Evidence map›Paper›PMID 8652811›Full record

GuidelineBlood1996

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

B D Cheson, J M Bennett, M Grever, N Kay, M J Keating, S O'Brien, K R Rai

5 registry-linked trialsAbstract readGuidelinePractice Guideline
PubMed
In one paragraph

Guideline in Blood, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 483 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
483citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00077922 phase2completednot on this mapstarted 2004, after this paper: background citation

A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2004 to 2011Enrolled15ConditionsLeukemia, Lymphocytic, ChronicArmsLMB-2
NCT00779883 phase1completednot on this mapstarted 2006, after this paper: background citation

A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)

TypeinterventionalSponsorMemgen, LLCRan2006 to 2008Enrolled9ConditionsChronic Lymphocytic LeukemiaArmsISF35
NCT00783588 phase1completednot on this mapstarted 2007, after this paper: background citation

A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914

TypeinterventionalSponsorMemgen, LLCRan2007 to 2008Enrolled4ConditionsChronic Lymphocytic LeukemiaArmsISF35
NCT01686386 phase1 / phase2unknown statusnot on this mapstarted 2010, after this paper: background citation

A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.

TypeinterventionalSponsorGruppo Italiano Studio LinfomiRan2010 to 2013Enrolled60ConditionsMultiple MyelomaArmsBendamustine, Lenalidomide, Dexamethasone
NCT03136497 phase1terminatednot on this mapstarted 2017, after this paper: background citation

Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)

TypeinterventionalSponsorHackensack Meridian HealthRan2017 to 2020Enrolled10ConditionsRelapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell LymphomaArms400mg ABT-199, Ibrutinib, Rituximab, 800mg ABT-199
3 · Its place in the literature

Who cites it

483 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.Journal of the National Comprehensive Cancer Network : JNCCN · 2015
    Guideline
  5. A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

423 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

B D ChesonNational Cancer Institute, Bethesda, MD 20892-7436, USA.
J M Bennett
M Grever
N Kay
M J Keating
S O'Brien
K R Rai

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsBone MarrowChromosome AberrationsClinical Trials as TopicDiagnosis, DifferentialHumansImmunophenotypingInfectionsLymphocyte CountNational Institutes of Health (U.S.)Neoplasm StagingNeutropeniaPatient SelectionTreatment OutcomeUnited States

Identifiers

PMID8652811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.